Abstract: A hydraulic control device for an automatic transmission is provided. The hydraulic control device can sets up any gear from a plurality of gears by causing any one of a plurality of frictional engagement elements to selectively carry out an engagement operation. The hydraulic control device includes: a regulator valve that regulates base oil pressure of hydraulic oil supplied from an oil pressure source; a relief valve provided in a lubricating oil passage connected from the regulator valve; and a line pressure switching section that sets up line pressure to low pressure to reduce the amount of lubricating oil in a region in which engagement hydraulic oil pressure does not require high engagement hydraulic oil pressure depending upon an operation state of a vehicle, and sets up the line pressure to high pressure when a target value of the engagement hydraulic oil pressure exceeds predetermined pressure.

Abstract: A hydraulic control device for an automatic transmission is provided. The hydraulic control device can sets up any gear from a plurality of gears by causing any one of a plurality of frictional engagement elements to selectively carry out an engagement operation. The hydraulic control device includes: a regulator valve that regulates base oil pressure of hydraulic oil supplied from an oil pressure source; a relief valve provided in a lubricating oil passage connected from the regulator valve; and a line pressure switching section that sets up line pressure to low pressure to reduce the amount of lubricating oil in a region in which engagement hydraulic oil pressure does not require high engagement hydraulic oil pressure depending upon an operation state of a vehicle, and sets up the line pressure to high pressure when a target value of the engagement hydraulic oil pressure exceeds predetermined pressure.

Abstract: To provide an intimal hyperplasia inhibitor useful for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or vascular stent placement or treatment of its progress. An intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I): [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group] or a pharmacologically acceptable salt thereof.

Abstract: An intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I): [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group] or a pharmacologically acceptable salt thereof.

Abstract: A pyrazolone derivative represented by general formula (I) or a salt thereof: ##STR1## [wherein one of X.sup.1 and X.sup.2 is ##STR2## (wherein A is a cyano group, a cyano C.sub.1-4 alkyl group, an amino group, an amino C.sub.1-4 alkyl group, an amidino group or a guanidino group, R.sup.1 and R.sup.2 are independently hydrogen atoms, halogen atoms, C.sub.1-6 alkyl groups or the like) or the like],the other of X.sup.1 and X.sup.2 is a C.sub.1-6 alkyl group, a C.sub.3-6 alkenyl group, an aryl C.sub.1-4 alkyl group or an aryl group,one of Y.sup.1 and Y.sup.2 is ##STR3## (wherein Q is an oxygen atom or a sulfur atom, Z.sup.1 is an oxygen atom, a --NR.sup.7 -- group or a --CHR.sup.7 -- group, Z.sup.2 is a cyclic C.sub.3-7 alkylene group, a C.sub.1-3 alkylene group, a --CH.sub.2 CO-- group or --CH.sub.2 CH.sub.2 CO-- group, Z.sup.3 is an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group or the like, Z.sup.4 is a C.sub.1-3 alkylene group, and Z.sup.5 is a carboxyl group or the like, andthe other of Y.

Abstract: An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: ##STR1## or a pharmaceutically acceptable salt of the compound.

Abstract: Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect of antitumor drugs.

Abstract: Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is a 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is either a CO.sub.2 R.sup.8 group or a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect or antitumor drugs.